Compare CYTK & QS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | QS |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.5B |
| IPO Year | 2004 | N/A |
| Metric | CYTK | QS |
|---|---|---|
| Price | $62.41 | $10.61 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 16 | 8 |
| Target Price | ★ $82.38 | $9.06 |
| AVG Volume (30 Days) | 2.2M | ★ 14.0M |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $87,211,000.00 | N/A |
| Revenue This Year | $346.43 | N/A |
| Revenue Next Year | $57.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2609.26 | N/A |
| 52 Week Low | $29.31 | $3.40 |
| 52 Week High | $70.98 | $19.07 |
| Indicator | CYTK | QS |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 39.51 |
| Support Level | $62.05 | $10.29 |
| Resistance Level | $66.59 | $11.60 |
| Average True Range (ATR) | 2.97 | 0.47 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 33.47 | 20.53 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.